See more : Enbridge Inc. (ENBBF) Income Statement Analysis – Financial Results
Complete financial analysis of Lexeo Therapeutics, Inc. Common Stock (LXEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexeo Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- SHRI VASUPRADA PLANTATIONS LIM (VASUPRADA.BO) Income Statement Analysis – Financial Results
- Bayer Aktiengesellschaft (BAYRY) Income Statement Analysis – Financial Results
- Alembic Limited (ALEMBICLTD.BO) Income Statement Analysis – Financial Results
- Fluidra, S.A. (FLUIF) Income Statement Analysis – Financial Results
- AeroVironment, Inc. (AVAV) Income Statement Analysis – Financial Results
Lexeo Therapeutics, Inc. Common Stock (LXEO)
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 654.00K | 1.66M | 518.48K |
| Cost of Revenue | 1.84M | 1.15M | 13.41K | 0.00 |
| Gross Profit | -1.84M | -491.00K | 1.64M | 518.48K |
| Gross Profit Ratio | 0.00% | -75.08% | 99.19% | 100.00% |
| Research & Development | 53.13M | 49.16M | 45.12M | 4.32M |
| General & Administrative | 15.38M | 12.00M | 7.17M | 787.50K |
| Selling & Marketing | -1.84M | 0.00 | 0.00 | 0.00 |
| SG&A | 13.54M | 12.00M | 7.17M | 787.50K |
| Other Expenses | 0.00 | -2.00K | -155.00 | 4.24K |
| Operating Expenses | 66.67M | 61.16M | 52.29M | 5.11M |
| Cost & Expenses | 68.51M | 61.16M | 52.29M | 5.11M |
| Interest Income | 2.87M | 1.33M | 15.00K | 0.00 |
| Interest Expense | 205.00K | 91.00K | 0.00 | 147.15K |
| Depreciation & Amortization | 1.84M | 1.15M | 13.41K | 4.24K |
| EBITDA | -66.67M | -58.04M | -50.62M | -4.58M |
| EBITDA Ratio | 0.00% | -8,874.77% | -3,054.25% | -884.04% |
| Operating Income | -68.51M | -60.51M | -50.64M | -4.59M |
| Operating Income Ratio | 0.00% | -9,252.14% | -3,055.94% | -884.86% |
| Total Other Income/Expenses | 2.12M | 1.23M | 15.00K | -565.00K |
| Income Before Tax | -66.39M | -59.28M | -50.62M | -5.15M |
| Income Before Tax Ratio | 0.00% | -9,063.76% | -3,055.04% | -993.83% |
| Income Tax Expense | 0.00 | 89.00K | -155.00 | 147.15K |
| Net Income | -66.39M | -59.28M | -50.62M | -5.15M |
| Net Income Ratio | 0.00% | -9,063.76% | -3,055.04% | -993.83% |
| EPS | -2.49 | -2.40 | -2.05 | -0.21 |
| EPS Diluted | -2.49 | -2.40 | -2.05 | -0.21 |
| Weighted Avg Shares Out | 26.65M | 24.67M | 24.67M | 24.67M |
| Weighted Avg Shares Out (Dil) | 26.65M | 24.67M | 24.67M | 24.67M |
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy
Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
Source: https://incomestatements.info
Category: Stock Reports